CANCERS 润色咨询

Cancers

出版年份:暂无数据 年文章数:15725 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:2.0% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2193127, encodeId=0049219312ef8, content=偏重的研究方向:分子生物学;肿瘤<br>经验分享:周期一个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:55:46 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:生信<br>经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向:肿瘤<br>经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问,接收meta吗,接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;肿瘤;生信<br>经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2024-03-14 Stou18389577351 来自广西

    偏重的研究方向:分子生物学;肿瘤
    经验分享:周期一个月左右

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2193127, encodeId=0049219312ef8, content=偏重的研究方向:分子生物学;肿瘤<br>经验分享:周期一个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:55:46 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:生信<br>经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向:肿瘤<br>经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问,接收meta吗,接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;肿瘤;生信<br>经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2024-02-19 jobhnw 来自安徽省

    2024年中科院预警杂志

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2193127, encodeId=0049219312ef8, content=偏重的研究方向:分子生物学;肿瘤<br>经验分享:周期一个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:55:46 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:生信<br>经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向:肿瘤<br>经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问,接收meta吗,接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;肿瘤;生信<br>经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2022-11-09 赵文超

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向:生信
    经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。

    7

    展开7条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2193127, encodeId=0049219312ef8, content=偏重的研究方向:分子生物学;肿瘤<br>经验分享:周期一个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:55:46 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:生信<br>经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向:肿瘤<br>经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问,接收meta吗,接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;肿瘤;生信<br>经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2024-01-22 地球超人 来自广东省

    麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2193127, encodeId=0049219312ef8, content=偏重的研究方向:分子生物学;肿瘤<br>经验分享:周期一个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:55:46 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:生信<br>经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向:肿瘤<br>经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问,接收meta吗,接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;肿瘤;生信<br>经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2024-01-01 ms7000000858427135 来自四川省

    偏重的研究方向:肿瘤
    经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2193127, encodeId=0049219312ef8, content=偏重的研究方向:分子生物学;肿瘤<br>经验分享:周期一个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:55:46 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:生信<br>经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向:肿瘤<br>经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问,接收meta吗,接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;肿瘤;生信<br>经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2023-10-28 ms7000001936665666 来自湖北省

    请问Pending review状态要持续几天呀?

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2193127, encodeId=0049219312ef8, content=偏重的研究方向:分子生物学;肿瘤<br>经验分享:周期一个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:55:46 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:生信<br>经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向:肿瘤<br>经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问,接收meta吗,接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;肿瘤;生信<br>经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2023-12-21 1226054bm42暂无昵称 来自广东省

    审稿速度:1.0 | 投稿命中率:95.0
    偏重的研究方向:肿瘤
    经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2193127, encodeId=0049219312ef8, content=偏重的研究方向:分子生物学;肿瘤<br>经验分享:周期一个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:55:46 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:生信<br>经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向:肿瘤<br>经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问,接收meta吗,接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;肿瘤;生信<br>经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2023-07-14 ms2000001241808309 来自山东省

    求问,接收meta吗,接不接受癌症护理方面的meta

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2193127, encodeId=0049219312ef8, content=偏重的研究方向:分子生物学;肿瘤<br>经验分享:周期一个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:55:46 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:生信<br>经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向:肿瘤<br>经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问,接收meta吗,接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;肿瘤;生信<br>经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2023-07-11 ms8000001285062090 来自江苏省

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:生物信息学;肿瘤;生信
    经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2193127, encodeId=0049219312ef8, content=偏重的研究方向:分子生物学;肿瘤<br>经验分享:周期一个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:55:46 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:生信<br>经验分享:生信干湿结合的文章,做的是肿瘤药物敏感性和标记物的方向,一开始也陆续投了十几个期刊,基本上都是被秒拒,最后投的这个杂志,10月13号投稿,两个礼拜审稿人意见回来了,给了十天时间返修,11月8号接收,效率真的很高,建议所有作者都要用edu邮箱,不然会被编辑要求提供CV。有很多朋友都说发文量大,明年可能被降到二区,但是对于急着毕业或者申请职称的医生还是很友好的,同样的期刊还有cancer science, genes,好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家,这个杂志必须所有作者,都要去点击邮件里那个“同意发表”才行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向:肿瘤<br>经验分享:只有一个细胞系的,会被拒吗?……小鼠转移肺癌模型的,除了llc细胞,还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:从投稿,送审,返修,到接收,整个过程非常快,不到一个月。编辑和期刊工作效率很高,也很nice。目前还是我们医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问,接收meta吗,接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;肿瘤;生信<br>经验分享:投稿到接收不到一个月,大概2天送审,5天小修,wb需要整膜,总的来说,快,创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2022-10-30 ms9000000045361890

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤
    经验分享:很好的一个杂志,审稿人提的意见非常有建设性,一审一个月整,就是版面费贵,投稿时格式有些要求

    3

    展开3条回复
共301条页码: 1/31页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分